| Name | Title | Contact Details |
|---|
For over 18 years, Tanner Pharma Group has provided highly specialized pharmaceutical services to its partners around the world. Leading pharmaceutical and biotech companies partner with Tanner Pharma to license and commercialize their products in challenging international markets, develop and manage their Global Access Programmes, and source comparator drugs for clinical trials and bioanalysis. By partnering with Tanner Pharma, manufacturers are able to focus on their primary markets and strategies while ensuring that the services they need will follow a strictly controlled protocol of quality. Headquartered in the U.S. with offices in London, São Paulo and Mexico City, Tanner Pharma Group`s reach includes Europe, Asia, the Middle East, Australia, Canada and Latin America. We measure our value as a company based on the lives we help to improve. For all of us involved in the pharmaceutical supply chain - manufacturers, distributors, pharmacists, doctors, and others - it is ultimately the patient that matters most. Therefore, we start each day with a renewed commitment to ethically supply unlicensed medicines to markets where access continues being a challenge.
Reimagining Healthcare. UrgentPoint is committed to combining health and wellness and meeting the patient where they are, every time. With a multispecialty medical group, a medical management company, and an electronic health records technology company...
Shionogi Inc. is the U.S. subsidiary of Shionogi & Co., Ltd., a 140-year-old global pharmaceutical company with headquarters in Osaka, Japan. In the U.S., Shionogi Inc. leverages our science-based heritage to develop and commercialize pharmaceutical products to treat unmet medical needs in our core areas of infectious diseases and pain, as well as other areas of high medical need, including chronic liver disease.
Miller Pharmacy is a Kansas City, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company`s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company`s two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.